Abdominal discomfort and altered bowel habits with mild IBS
Potential benefit studied: Possible improvement in digestive symptoms
Supporting researchA human study found that a lecithin-based boswellia preparation lowered IBS symptom scores and reduced the need for rescue medication over six months.
Sixty-nine participants completed six months of follow-up. Thirty-five received one daily tablet of Casperome, a lecithin-based Boswellia preparation, and 34 received standard management involving diet and symptom medicines when needed. The abstract does not specify tablet strength.
Casperome has a particular delivery system that is not established for Mobility's 100 mg Boswellia at 30% AKBA. The study does not demonstrate digestive benefits for Mobility's Boswellia and moringa combination.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.